Tumor-Associated Macrophage-Derived TGF-β1 Activates GLI2 via the Smad2/3 Signaling Pathway to Affect Cisplatin Resistance in Lung Adenocarcinoma
Technology in Cancer Research & Treatment · 2024
DOI: 10.1177/15330338241274337 ↗Kurz gefasst
Fachartikel in der Zeitschrift Technology in Cancer Research & Treatment, 2024. Verfasst von Xiaoling Lan und 4 weiteren Autor:innen. Beteiligte Einrichtung: Medical School, Jinan University, Guangzhou, China. Hauptthemen laut MEDLINE: Zinc Finger Protein Gli2, Drug Resistance, Neoplasm, Transforming Growth Factor beta1, Smad3 Protein. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: 2023 Guangxi University Young and Middle aged Teachers Research Foundation Ability Enhancement Project.
Abstract (Originalsprache)
Background
Transforming growth factor-β1 (TGF-β1) is an immunosuppressive cytokine that is highly expressed in the tumor microenvironment (TME) of lung adenocarcinoma (LUAD). TGF-β1 plays important roles in regulating tumor metastasis and chemotherapy resistance. However, the specific molecular mechanisms by which TGF-β1 regulates cisplatin resistance in the TAM of LUAD remain unclear. Materials and methods THP-1 induced macrophages were co-cultured with A549 and H1975 cells, and subsequently transfected with silencing TGF-β1 (siTGF-β1), GLI2 (siGLI2), a GLI2 overexpression plasmid, and their negative controls. Cellular activity was measured by CCK-8 and colony formation assays. Cell apoptosis was evaluated by flow cytometry and TUNEL staining. Transwell assays were performed to assess cell migration and invasion capabilities. The levels of Smad2/3, GLI2, cyclin D, and cyclin E expression were evaluated by qPCR, western blotting, and immunofluorescence methods. TGF-β1 levels were determined by ELISA.
Results
Macrophages suppressed the apoptosis and promoted the migration and invasion of LUAD cells. TAM siTGF-β1 downregulated the Smad2/3 signaling pathways and GLI2 expression, deceased cell proliferation, and promoted apoptosis. SiGLI2 increased apoptosis and decreased the proliferation of LUAD cell lines. GLI2 decreased cisplatin resistance in LUAD cells.
Conclusion
High expression of TGF-β1 in the TAM positively activates GLI2 expression via the Smad2/3 pathway, which subsequently regulates cyclin D and cyclin E expression, and promotes the cisplatin resistance of LUAD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Medical School, Jinan University, Guangzhou, China.
- Department of Oncology and Chemotherapy, Afiliated Hospital of Youjiang Medical University for Nationalities, Baise, China.
- Department of Burns, Plastic Surgery and Wound Repair, Afiliated Hospital of Youjiang Medical University for Nationalities, Baise, China.
- Department of Endocrinology, Afiliated Hospital of Youjiang Medical University for Nationalities, Baise, China.
- Graduate School, Youjiang Medical University for Nationalities, Baise, China.
ORCID-Profile: Biaoliang Wu
Förderung
- 2023 Guangxi University Young and Middle aged Teachers Research Foundation Ability Enhancement Project
Zitieren
APA
Lan, X., Wei, D., Fang, L., Wu, X., & Wu, B. (2024). Tumor-Associated Macrophage-Derived TGF-β1 Activates GLI2 via the Smad2/3 Signaling Pathway to Affect Cisplatin Resistance in Lung Adenocarcinoma. Technology in Cancer Research & Treatment. https://doi.org/10.1177/15330338241274337
Vancouver
Lan X, Wei D, Fang L, Wu X, Wu B. Tumor-Associated Macrophage-Derived TGF-β1 Activates GLI2 via the Smad2/3 Signaling Pathway to Affect Cisplatin Resistance in Lung Adenocarcinoma. Technology in Cancer Research & Treatment. 2024. doi:10.1177/15330338241274337
BibTeX
@article{Lan2024,
author = {Lan, Xiaoling and Wei, Dalong and Fang, Lini and Wu, Xiangsheng and Wu, Biaoliang},
title = {Tumor-Associated Macrophage-Derived TGF-β1 Activates GLI2 via the Smad2/3 Signaling Pathway to Affect Cisplatin Resistance in Lung Adenocarcinoma},
journal = {Technology in Cancer Research & Treatment},
year = {2024},
doi = {10.1177/15330338241274337}
}
EUVIMED